Your browser doesn't support javascript.
loading
Treatment of Obesity with Thyroid hormones in Europe. Data from the THESIS* Collaboration.
Galofré, J C; Díez, J J; Attanasio, R; Nagy, E V; Negro, R; Papini, E; Perros, P; Zarkovic, M; Akarsu, E; Alevizaki, M; Ayvaz, G; Bednarczuk, T; Beleslin, B N; Berta, E; Bodor, M; Borissova, A M; Boyanov, M; Buffet, C; Burlacu, M C; Dobnig, H; Fadeyev, V; Field, B C T; Fliers, E; Führer, D; Hakala, T; Jiskra, J; Kopp, P; Krebs, M; Krsek, M; Kuzma, M; Lantz, M; Lazúrová, I; Leenhardt, L; Luchytskiy, V; Puga, F M; McGowan, A; Metso, S; Moran, C; Morgunova, T; Niculescu, D A; Peric, B; Planck, T; Poiana, C; Robenshtok, E; Rosselet, P O; Ruchala, M; Riis, K R; Shepelkevich, A; Tronko, M; Unuane, D.
Afiliación
  • Galofré JC; Department of Endocrinology and Nutrition, Clínica Universidad de Navarra, Pío XII, 36., 31080, Pamplona, Spain. jcgalofre@unav.es.
  • Díez JJ; Instituto de Investigación Sanitaria de Navarra (IdiSNA), Pamplona, Spain. jcgalofre@unav.es.
  • Attanasio R; Thyroid Task Force From the Sociedad Española de Endocrinología y Nutrición (SEEN), Madrid, Spain. jcgalofre@unav.es.
  • Nagy EV; Thyroid Task Force From the Sociedad Española de Endocrinología y Nutrición (SEEN), Madrid, Spain.
  • Negro R; Department of Endocrinology, Hospital Universitario Puerta de Hierro Majadahonda, Madrid, Spain.
  • Papini E; Instituto de Investigación Sanitaria Puerta de Hierro Segovia de Arana, Majadahonda, Madrid, Spain.
  • Perros P; Department of Medicine, Universidad Autónoma de Madrid, Madrid, Spain.
  • Zarkovic M; Scientific Committee Associazione Medici Endocrinologi, Milan, Italy.
  • Akarsu E; Division of Endocrinology, Department of Medicine, Faculty of Medicine, University of Debrecen, Debrecen, Hungary.
  • Alevizaki M; Division of Endocrinology, V. Fazzi Hospital, Lecce, Italy.
  • Ayvaz G; Department of Endocrinology and Metabolism, Regina Apostolorum Hospital, Rome, Italy.
  • Bednarczuk T; Institute of Translational and Clinical Research, Newcastle University, Newcastle Upon Tyne, UK.
  • Beleslin BN; Faculty of Medicine, University of Belgrade, Belgrade, Serbia.
  • Berta E; Division of Endocrinology, Department of Internal Medicine, Faculty of Medicine, Gaziantep University, Gaziantep, Turkey.
  • Bodor M; Endocrine Unit and Diabetes Centre, Department of Clinical Therapeutics, School of Medicine, Alexandra Hospital, National and Kapodistrian University of Athens, Athens, Greece.
  • Borissova AM; Department of Endocrinology and Metabolism, Koru Ankara Hospital, Kizilirmak, Ankara, Turkey.
  • Boyanov M; Department of Internal Medicine and Endocrinology, Medical University of Warsaw, Warsaw, Poland.
  • Buffet C; Faculty of Medicine, University of Belgrade, Belgrade, Serbia.
  • Burlacu MC; Institute of Endocrinology, Diabetes and Metabolic Disorders, Univeristy Clinical Center of Serbia, Belgrade, Serbia.
  • Dobnig H; Division of Endocrinology, Department of Medicine, Faculty of Medicine, University of Debrecen, Debrecen, Hungary.
  • Fadeyev V; Division of Endocrinology, Department of Medicine, Faculty of Medicine, University of Debrecen, Debrecen, Hungary.
  • Field BCT; Clinic of Endocrinology and Metabolism, Medical Faculty, University Hospital "Sofiamed", Sofia University "Saint Kliment Ohridski", Sofia, Bulgaria.
  • Fliers E; Clinic of Endocrinology and Metabolism, University Hospital "Alexandrovska", Sofia, Bulgaria.
  • Führer D; Department of Internal Medicine, Medical University Sofia, Sofia, Bulgaria.
  • Hakala T; Thyroid Disease and Endocrine Tumor Department, Sorbonne Universitè, Hôpital Pitié-Salpêtriére, Paris, France.
  • Jiskra J; Department of Endocrinology Diabetology and Nutrition, Cliniques Universitaires St-Luc, Université Catholique de Louvain, Brussels, Belgium.
  • Kopp P; Thyroid and Osteoporosis Praxis, Kumberg, Austria.
  • Krebs M; Thyroid Practice for Radiofrequency Ablation, Vienna, Austria.
  • Krsek M; Department of Endocrinology No. 1, N.V. Sklifosovsky Institute of Clinical Medicine, I.M. Sechenov First Moscow State Medical University, Moscow, Russian Federation.
  • Kuzma M; Section of Clinical Medicine, Faculty of Health & Medical Sciences, University of Surrey, Guildford, Surrey, UK.
  • Lantz M; Department of Endocrinology & Metabolism, Amsterdam UMC, University of Amsterdam, Amsterdam, The Netherlands.
  • Lazúrová I; Department of Endocrinology, Diabetes and Metabolism, University Hospital Essen, University-Duisburg-Essen, Essen, Germany.
  • Leenhardt L; Department of Surgery, Tampere University Hospital, Tampere, Finland.
  • Luchytskiy V; 3rd Department of Medicine, 1st Faculty of Medicine, Charles University, General University Hospital, Prague, Czech Republic.
  • Puga FM; Division of Endocrinology, Diabetes and Metabolism, University of Lausanne, Lausanne, Switzerland.
  • McGowan A; Internal Medicine III, Division of Endocrinology and Metabolism, Medical University of Vienna, Vienna, Austria.
  • Metso S; 3rd Department of Medicine, 1st Faculty of Medicine, Charles University, General University Hospital, Prague, Czech Republic.
  • Moran C; 5th Department of Internal Medicine, Medical Faculty of Comenius, University and University Hospital, Bratislava, Slovakia.
  • Morgunova T; Department of Endocrinology, Skåne University Hospital, Malmö, Sweden.
  • Niculescu DA; 1st Department of Internal Medicine of the Medical Faculty, P.J. Safárik University Kosice, Kosice, Slovakia.
  • Peric B; Thyroid Disease and Endocrine Tumor Department, Sorbonne Universitè, Hôpital Pitié-Salpêtriére, Paris, France.
  • Planck T; Department of Reproductive Endocrinology, Institute of Endocrinology and Metabolism Named after V.P. Komissarenko, National Academy of Medical Science of Ukraine, Kyiv, Ukraine.
  • Poiana C; Endocrinology, Diabetes and Metabolism Service, Centro Hospitalar Universitário de Santo António, Porto, Portugal.
  • Robenshtok E; Robert Graves Institute, Tallaght University Hospital, Dublin, Ireland.
  • Rosselet PO; Department of Endocrinology, Tampere University Hospital, Tampere, Finland.
  • Ruchala M; Diabetes & Endocrinology Section, Beacon Hospital, Beacon Court, Dublin, Ireland.
  • Riis KR; School of Medicine, University College Dublin, Dublin, Ireland.
  • Shepelkevich A; Department of Endocrinology No. 1, N.V. Sklifosovsky Institute of Clinical Medicine, I.M. Sechenov First Moscow State Medical University, Moscow, Russian Federation.
  • Tronko M; Department of Endocrinology, Carol Davila University of Medicine and Pharmacy, Bucharest, Romania.
  • Unuane D; Department of Endocrinology, Diabetes and Metabolic Diseases "Mladen Sekso", University Hospital Center "Sisters of Mercy", Zagreb, Croatia.
J Endocrinol Invest ; 2024 Jun 15.
Article en En | MEDLINE | ID: mdl-38878126
ABSTRACT

PURPOSE:

The use of thyroid hormones (TH) to treat obesity is unsupported by evidence as reflected in international guidelines. We explored views about this practice, and associations with respondent characteristics among European thyroid specialists.

METHODS:

Specialists from 28 countries were invited to a survey via professional organisations. The relevant question was whether "Thyroid hormones may be indicated in biochemically euthyroid patients with obesity resistant to lifestyle interventions".

RESULTS:

Of 17,232 invitations 5695 responses were received (33% valid response rate; 65% women; 90% endocrinologists). Of these, 290 (5.1%) stated that TH may be indicated as treatment for obesity in euthyroid patients. This view was commoner among non-endocrinologists (8.7% vs. 4.7%, p < 0.01), private practice (6.5% vs. 4.5%, p < 0.01), and varied geographically (Eastern Europe, 7.3%; Southern Europe, 4.8%; Western Europe, 2.7%; and Northern Europe, 2.5%). Respondents from Northern and Western Europe were less likely to use TH than those from Eastern Europe (p < 0.01). Gross national income (GNI) correlated inversely with this view (OR 0.97, CI 0.96-0.97; p < 0.001). Having national guidelines on hypothyroidism correlated negatively with treating obesity with TH (OR 0.71, CI 0.55-0.91).

CONCLUSIONS:

Despite the lack of evidence, and contrary to guidelines' recommendations, about 5% of respondents stated that TH may be indicated as a treatment for obesity in euthyroid patients resistant to life-style interventions. This opinion was associated with (i) respondent characteristics being non-endocrinologist, working in private practice, treating a small number of hypothyroid patients annually and (ii) national characteristics prevalence of obesity, Eastern Europe, low GNI and lack of national hypothyroidism guidelines.
Palabras clave
Texto completo
Añadir a Mi BVS
Imprimir
XML
PubMed Links
Buscar en Google

Texto completo: 1 Colección: 01-internacional Base de datos: MEDLINE Idioma: En Revista: J Endocrinol Invest Año: 2024 Tipo del documento: Article País de afiliación: España Pais de publicación: Italia
Texto completo
Añadir a Mi BVS
Imprimir
XML
PubMed Links
Buscar en Google

Texto completo: 1 Colección: 01-internacional Base de datos: MEDLINE Idioma: En Revista: J Endocrinol Invest Año: 2024 Tipo del documento: Article País de afiliación: España Pais de publicación: Italia